Top 10 drugs from new Merck, new Pfizer

UPDATED: Added direct link to Merck release

The Associated Press has put out a helpful list of Merck's top-selling drugs for the fourth quarter, now that it has merged with Schering-Plough. So we thought we'd take a look at the other megamerger--Pfizer and Wyeth--and Merck's list, too. The names on both lists are familiar, and you'll notice that each list includes some drugs brought in by the respective mergers. Here's Pfizer's list to start:

Lipitor, cholesterol drug, $3.175 billion, a 1 percent increase over the same period last year;

Lyrica, for fibromyalgia and nerve pain, $820 million, a 17 percent increase;

Celebrex, an arthritis pain drug, $669 million, up 1 percent;

Viagra, erectile dysfunction, $549 million, up 9 percent;
Effexor, antidepressant, $520 million;
Xalatan/Xalacom, eye pressure, $499 million, up 10 percent;

Norvasc, for high blood pressure, $486 million, down 10 percent;
Enbrel, anti-inflammatory, $378 million;

Zyvox, antibiotic, $330 million, up 16 percent;

Detrol/Detrol LA, overactive bladder, $309 million, down 1 percent;

Now, here's the Merck version, from the AP (percentages ours):

Singulair, Asthma/Allergies, $1.26 billion, up more than 12 percent;

Cozaar/Hyzaar, high blood pressure, $955 million, up about 8 percent;

Januvia/Janumet, diabetes, $760 million, up close to 43 percent;

Remicade, rheumatoid arthritis, $635 million, up about 29 percent;

Zetia, cholesterol, $614 million, up 10 percent;

Vytorin, cholesterol, $577 million, up roughly 2 percent;

Temodar, cancer treatment, $292 million, up close to 21 percent;

Nasonex, allergies, $286 million, up about 2 percent;

Fosamax, osteoporosis, $285 million, down 10 percent; and

Gardasil, HPV vaccine, $277 million, down 3 percent.

- get Pfizer's Q4 financial report [1]
- check out the Merck release [2]